Comparative Pharmacology
Head-to-head clinical analysis: ARICEPT versus DONEPEZIL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARICEPT versus DONEPEZIL HYDROCHLORIDE.
ARICEPT vs DONEPEZIL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine levels in the synaptic cleft of the central nervous system.
Reversible inhibitor of acetylcholinesterase, increasing acetylcholine concentration in the synaptic cleft of the central nervous system.
Initial: 5 mg orally once daily for 4-6 weeks; may increase to 10 mg once daily. Maximum: 10 mg per day. Route: oral. Frequency: once daily.
Alzheimer's disease: Initial 5 mg orally once daily at bedtime for 4-6 weeks, increase to 10 mg once daily. Maximum dose 10 mg/day.
None Documented
None Documented
70 hours (terminal elimination half-life; steady-state reached in 15-21 days; once-daily dosing appropriate)
Terminal elimination half-life approximately 70 hours (range 50-100 hours), allowing once-daily dosing; steady-state reached in 14-21 days
Renal (57% unchanged drug, 17% as metabolites), fecal (30%), biliary (minimal)
Renal (26% unchanged), fecal (57%, primarily as metabolites via biliary excretion)
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor